The Patent Finder

Biovitrum AB (publ)

Also on record
Records under this name other than patents Biovitrum AB (publ) holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Biovitrum AB (publ)

PatentTitleStatus Expires Confidence
US 8,304,387Therapeutic Formulations of Keratinocyte Growth Factor
Formerly held
In force
 · High confidence
In forceHigh confidence
US 6,465,467Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
Formerly held
Term ended
Term ended May 19, 2020 · From the USPTO record
Term endedTerm ended May 19, 2020From the USPTO record
US 8,030,316Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine
Formerly held
Lapsed on the fee record
Ended Oct 4, 2019 · From the USPTO record
Lapsed on the fee recordEnded Oct 4, 2019From the USPTO record
US 7,129,354Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds
Formerly held
Lapsed on the fee record
Ended Oct 31, 2018 · From the USPTO record
Lapsed on the fee recordEnded Oct 31, 2018From the USPTO record
US 7,820,677Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine
Formerly held
Lapsed on the fee record
Ended Oct 26, 2018 · From the USPTO record
Lapsed on the fee recordEnded Oct 26, 2018From the USPTO record
US 7,812,0174-substituted indole and indoline compounds
Formerly held
Lapsed on the fee record
Ended Oct 12, 2018 · From the USPTO record
Lapsed on the fee recordEnded Oct 12, 2018From the USPTO record
US 8,835,439Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases
Formerly held
Lapsed on the fee record
Ended Sep 16, 2018 · From the USPTO record
Lapsed on the fee recordEnded Sep 16, 2018From the USPTO record
US 7,071,180Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
Formerly held
Lapsed on the fee record
Ended Jul 4, 2018 · From the USPTO record
Lapsed on the fee recordEnded Jul 4, 2018From the USPTO record
US 6,248,319Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
Term ended
Term ended Jun 19, 2018 · From the USPTO record
Term endedTerm ended Jun 19, 2018From the USPTO record
US 6,218,148DNS encoding stem cell factor
Term ended
Term ended Apr 17, 2018 · From the USPTO record
Term endedTerm ended Apr 17, 2018From the USPTO record
10 of 61 patents shown.
Pro members see all 61.
Pro members: see all 61 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited